CTLA4 and neuroblastoma: Since the lack of therapeutic benefit of anti-PD1 treatment against idMMR neuroblastoma tumors was not associated with tumor immunogenicity but rather the induction of inhibitory checkpoint molecules on TILs, we decided to determine whether such a phenomenon was unique to anti-PD1 treatment or could be reproduced with anti-CTLA4 therapy.